SLC10A1 Antibody

What is SLC10A1 and why is it important in research?

SLC10A1 (Solute Carrier Family 10 Member 1), also known as NTCP (Na+/taurocholate cotransporting polypeptide), functions as a major transporter of conjugated bile salts from plasma into hepatocytes. It plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins . The protein is strictly dependent on extracellular sodium and exhibits broad substrate specificity, transporting various bile acids and non-bile acid organic compounds . Most significantly for infectious disease research, SLC10A1 acts as a functional receptor for hepatitis B virus (HBV) , making it a critical target for studying HBV infection mechanisms.

When selecting an SLC10A1 antibody, consider:

• Target epitope location: Different antibodies target distinct regions of SLC10A1 (N-terminal, middle region, or C-terminal) . The epitope location can affect antibody performance in different applications and under various sample preparation conditions.

• Species reactivity: Verify cross-reactivity with your species of interest. Many SLC10A1 antibodies react with human, mouse, and rat samples, but sequence differences exist between species .

• Clonality: Polyclonal antibodies often provide higher sensitivity but potential batch-to-batch variability, while monoclonal antibodies (particularly recombinant monoclonals) offer higher specificity and consistency .

• Validation data: Look for antibodies with extensive validation across multiple applications relevant to your research question .

What are the optimal conditions for SLC10A1 detection in Western blotting?

For optimal Western blot detection of SLC10A1:

• Sample preparation: Liver tissue lysates show the strongest signal for SLC10A1 detection . When using cell lines, hepatocyte-derived lines are recommended.

• Expected molecular weight: The calculated molecular weight of SLC10A1 is approximately 38-39 kDa , but the observed molecular weight in SDS-PAGE can range from 38-65 kDa depending on glycosylation and other post-translational modifications .

• Antibody dilution: A starting dilution of 1:1000 is recommended for most SLC10A1 antibodies in Western blotting applications .

• Controls: Include human liver tissue lysate as a positive control when possible .

How can I optimize immunohistochemical detection of SLC10A1?

For successful IHC detection of SLC10A1:

• Fixation: Formalin-fixed paraffin-embedded (FFPE) tissues are compatible with most SLC10A1 antibodies .

• Antibody dilution: A typical dilution range for IHC is 1:200-1:2500, with 1:1000 being a good starting point .

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended for most FFPE tissues.

• Detection system: Both DAB staining (for brightfield microscopy) and fluorescent secondary antibodies can be used effectively with SLC10A1 primary antibodies .

• Expected localization: SLC10A1 should localize to the basolateral membrane of hepatocytes . Any other pattern may indicate non-specific staining.

What approaches can address weak or non-specific SLC10A1 staining?

When troubleshooting suboptimal SLC10A1 antibody performance:

• For weak signals:

  • Increase antibody concentration gradually

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance signal amplification systems (e.g., biotin-streptavidin)

  • Optimize antigen retrieval conditions

  • Consider tissue-specific fixation issues

• For non-specific signals:

  • Use more stringent washing conditions

  • Include blocking peptides corresponding to the immunogen sequence

  • Decrease antibody concentration

  • Validate with knockout/knockdown controls

  • Try a different antibody targeting an alternative epitope

How can SLC10A1 antibodies be utilized in HBV research?

SLC10A1/NTCP antibodies are valuable tools in HBV research:

• Receptor expression studies: Characterize SLC10A1 expression levels in different cell lines to predict susceptibility to HBV infection .

• Blocking experiments: Some antibodies may be used to block the HBV-SLC10A1 interaction in vitro, providing insights into viral entry mechanisms.

• Genetic variant analysis: SLC10A1 variants (particularly the Ser267Phe variant, rs2296651) have been investigated for their impact on HBV infection susceptibility . Antibodies that can distinguish these variants are valuable for functional studies.

• Co-localization studies: Dual staining with HBV proteins and SLC10A1 can reveal receptor-virus interactions in infected cells.

The Ser267Phe variant (rs2296651) in exon 4 of SLC10A1 has been extensively studied for its association with HBV infection risk, though a comprehensive assessment in Southern Chinese populations found no significant association between SLC10A1 genetic variants and persistent HBV infection .

What experimental models are suitable for SLC10A1 functional studies?

Suitable models for SLC10A1 functional studies include:

• Primary hepatocytes: Closest to physiological expression of SLC10A1, but challenging to maintain in culture.

• Hepatocyte cell lines: HepG2 and Huh7 cells often used, but may have variable endogenous SLC10A1 expression.

• Xenopus oocytes: Injection of in vitro transcribed SLC10A1 cRNA into Xenopus oocytes has been used to study transport function, with demonstrated Na⁺-dependent taurocholate uptake inhibited by various bile acid derivatives .

• Transgenic mice: Models with modified SLC10A1 expression can provide insights into in vivo function.

When designing such studies, it's critical to confirm SLC10A1 expression using validated antibodies before conducting functional assays.

How should I design controls for SLC10A1 antibody experiments?

Essential controls for SLC10A1 antibody experiments:

• Positive tissue control: Human, mouse or rat liver tissue, depending on the species reactivity of your antibody .

• Negative tissue control: Non-hepatic tissues with minimal SLC10A1 expression.

• Antibody controls:

  • Isotype control (same species and isotype as your primary antibody)

  • Secondary antibody-only control (omit primary antibody)

  • Blocking peptide competition (preincubate antibody with immunogen peptide)

• Genetic controls (when possible):

  • SLC10A1 knockout or knockdown samples

  • Overexpression systems with tagged SLC10A1

How can SLC10A1 antibodies be used in studies of bile acid transport disorders?

SLC10A1 antibodies can be valuable tools for investigating bile acid transport disorders:

• Expression analysis: Quantify SLC10A1 protein levels in patient-derived samples compared to healthy controls.

• Localization studies: Determine if pathological conditions affect SLC10A1 trafficking to the basolateral membrane of hepatocytes.

• Functional correlation: Combine antibody-based detection with bile acid uptake assays to correlate expression levels with transport function.

• Therapeutic development: Screen compounds that might restore proper SLC10A1 expression or function in disease states.

What approaches exist for quantifying SLC10A1 expression in research and clinical samples?

For quantitative analysis of SLC10A1 expression:

• Western blotting: Semi-quantitative approach using densitometry normalized to loading controls. Recommended dilutions range from 1:300-1:5000 .

• Flow cytometry: Can quantify SLC10A1 expression at the single-cell level in cell suspensions. Typical antibody dilutions range from 1:20-1:100 .

• Quantitative immunohistochemistry: Digital image analysis of IHC slides can provide semi-quantitative data on SLC10A1 expression and localization.

• ELISA: Some SLC10A1 antibodies have been validated for ELISA, allowing for more precise quantification in lysates .

• Proteomics approaches: Mass spectrometry-based approaches may offer more absolute quantification but require specialized equipment.

For all quantitative applications, standard curves with recombinant SLC10A1 protein and validation with multiple antibodies targeting different epitopes are recommended for robust results.

How do storage and handling conditions affect SLC10A1 antibody performance?

Proper storage and handling are critical for maintaining SLC10A1 antibody performance:

• Storage temperature: Store antibodies at -20°C for long-term storage .

• Aliquoting: Upon receipt, aliquot antibodies to avoid repeated freeze-thaw cycles .

• Working stock: For regular use, keep a working aliquot at 4°C for up to one month .

• Reconstitution: For lyophilized antibodies, reconstitute with the recommended volume of distilled water or buffer to achieve the specified concentration (typically 0.5-1 mg/mL) .

• Centrifugation: If not completely clear after standing at room temperature, briefly centrifuge before use .

Most SLC10A1 antibodies are stable for several weeks at 4°C as long as contamination is prevented .

What considerations are important when using SLC10A1 antibodies for co-localization studies?

For successful co-localization studies with SLC10A1:

• Antibody compatibility: Ensure primary antibodies are from different host species to avoid cross-reactivity of secondary antibodies.

• Epitope accessibility: Sequential staining may be necessary if both targets require the same antigen retrieval conditions.

• Expected localization patterns:

  • SLC10A1: Basolateral membrane of hepatocytes

  • Common co-staining partners: Other transporters (like BSEP), HBV surface antigens, or hepatocyte markers

• Controls: Include single-stained samples to confirm the specificity of each antibody and exclude bleed-through in fluorescence channels.

• Image acquisition: Use sequential scanning rather than simultaneous acquisition to minimize crosstalk between fluorophores.